Skip to main content
. Author manuscript; available in PMC: 2018 Nov 10.
Published in final edited form as: Oncogene. 2018 May 10;37(33):4534–4545. doi: 10.1038/s41388-018-0282-4

Figure 6. Targeting HERV-K NP9 significantly suppresses KSHV-induced tumorigenesis in vivo.

Figure 6

(A-C) The Np9 stably “knock-down” TIVE-LTC or control cells (approximately 5 × 105 cells were mixed at a ratio of 1:1 with growth factor-depleted Matrigel) were injected subcutaneously into the right and left flanks of nude mice, respectively. The mice were observed and measured every 2~3 d for the presence of palpable tumors for 30 d. Error bars represent the S.D. from 2 independent experiments. * = p<0.05, ** = p<0.01. (D-E) Protein expression within tumor tissues from representative injected mice was measured by using immunohistochemistry or immunoblots, respectively.